Splenic vein thrombosis
ICD-10 D73.5 · ICD-11 DB98.4

Treatment of Splenic Vein Thrombosis in Symptomatic Acute Splanchnic Vein Thrombosis Associated with Cancer

Splenic vein thrombosis occurring as part of a symptomatic acute splanchnic vein thrombosis in a patient with an active cancer diagnosis requires a specific, evidence-informed treatment approach. The presence of malignancy shapes both the choice and duration of anticoagulant therapy.

Clinical Scenario
This protocol addresses patients with cancer-associated symptomatic acute splanchnic vein thrombosis. The underlying malignancy represents a persistent thrombotic risk factor and directly influences the selection of anticoagulation strategy — including the type of agent and the intended duration of treatment.
Treatment Approach & Goals
Anticoagulation therapy forms the core of management. The recommended agents include a specific class of injectable therapy and a class of direct oral anticoagulants — however, the preferred agent depends on the type and location of the cancer, the presence of gastrointestinal or genitourinary involvement, bleeding risk, and concurrent systemic therapies. The full decision framework, duration criteria, and conditions for extending therapy are specified in the complete protocol.
Clinical goal: achieve the highest possible vessel recanalization to reduce splanchnic hypertension and associated bleeding risk.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jth.14836
  • In patients with cancer-associated symptomatic acute splanchnic vein thrombosis, we recommend LMWH or DOACs. We suggest LMWH in patients with luminal gastrointestinal cancer, active gastrointestinal mucosal abnormalities, genitourinary cancer at high risk of bleeding, or receiving current systemic therapy with potentially relevant drug-drug interactions with DOACs.
  • 3 to 6-month anticoagulation irrespective of thrombosis extension and underlying risk factors.
  • Longer course or indefinite anticoagulation if: thrombosis progression or recurrence after treatment discontinuation; unprovoked splanchnic vein thrombosis; persistent thrombotic risk factor.
  • Treatment of occlusive or non-occlusive acute splanchnic vein thrombosis aims to prevent intestinal infarction or ischemia, and achieve the highest possible vessel recanalization to reduce splanchnic hypertension and bleeding risk.
View source ↗